CY1123792T1 - Συνθεσεις για καταστολη σχηματiσμου αναστολεων εναντι του παραγοντα viii σε ασθενεις με αιμορροφιλια α - Google Patents
Συνθεσεις για καταστολη σχηματiσμου αναστολεων εναντι του παραγοντα viii σε ασθενεις με αιμορροφιλια αInfo
- Publication number
- CY1123792T1 CY1123792T1 CY20201101009T CY201101009T CY1123792T1 CY 1123792 T1 CY1123792 T1 CY 1123792T1 CY 20201101009 T CY20201101009 T CY 20201101009T CY 201101009 T CY201101009 T CY 201101009T CY 1123792 T1 CY1123792 T1 CY 1123792T1
- Authority
- CY
- Cyprus
- Prior art keywords
- protein
- formation
- patients
- reactions
- coagulation factor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/28—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Vibrionaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8201—Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation
- C12N15/8214—Plastid transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
- C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/0102—Alpha-glucosidase (3.2.1.20)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01022—Alpha-galactosidase (3.2.1.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Η θεραπεία αντικατάστασης πρωτεϊνών για ασθενείς με αιμορροφιλία ή άλλες κληρονομικές ανεπάρκειες πρωτεΐνης συχνά περιπλέκεται από παθογόνες αποκρίσεις αντισωμάτων, συμπεριλαμβανομένων αντισωμάτων που εξουδετερώνουν τη θεραπευτική πρωτεΐνη ή που προδιαθέτουν σε αναφυλακτικές αντιδράσεις που ενδέχεται να θέτουν σε κίνδυνο τη ζωή με σχηματισμό lgE. Χρησιμοποιώντας την αιμορροφιλία ποντικού ως μοντέλο, έχουμε αναπτύξει ένα προφυλακτικό πρωτόκολλο ενάντια σε τέτοιες αντιδράσεις που δεν είναι επεμβατικές και δεν περιλαμβάνουν ανοσοκαταστολή ή γενετικό χειρισμό των κυττάρων του ασθενούς. Στοματική παράδοση του παράγοντα πήξης που εκφράζεται σε χλωροπλάστες, βιοενθυλακωμένη σε φυτικά κύτταρα, μπλοκάρει αποτελεσματικά τον σχηματισμό ανασταλτικών αντισωμάτων στη θεραπεία αντικατάστασης πρωτεϊνών. Οι τίτλοι αναστολέων ήταν ως επί το πλείστον μη ανιχνεύσιμοι και έως και 100 φορές χαμηλότεροι σε υποκείμενα υπό αγωγή σε σύγκριση με τους ελέγχους. Επιπλέον, αυτή η θεραπεία εξάλειψε θανατηφόρες αναφυλακτικές αντιδράσεις που εμφανίστηκαν μετά από 4 έως 6 εκθέσεις σε πρωτεΐνη ενδοφλέβιου παράγοντα πήξης.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361905069P | 2013-11-15 | 2013-11-15 | |
| US201361905071P | 2013-11-15 | 2013-11-15 | |
| PCT/US2014/065994 WO2015073988A1 (en) | 2013-11-15 | 2014-11-17 | Compositions and methods for suppression of inhibitor formation against factor viii in hemophilia a patients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1123792T1 true CY1123792T1 (el) | 2022-03-24 |
Family
ID=53058150
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20201101009T CY1123792T1 (el) | 2013-11-15 | 2020-10-22 | Συνθεσεις για καταστολη σχηματiσμου αναστολεων εναντι του παραγοντα viii σε ασθενεις με αιμορροφιλια α |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US10233216B2 (el) |
| EP (2) | EP3068869B1 (el) |
| AU (1) | AU2014348289B2 (el) |
| CA (1) | CA2967269C (el) |
| CY (1) | CY1123792T1 (el) |
| DK (1) | DK3068869T3 (el) |
| ES (1) | ES2821882T3 (el) |
| HR (1) | HRP20201680T1 (el) |
| HU (1) | HUE050869T2 (el) |
| LT (1) | LT3068869T (el) |
| PL (1) | PL3068869T3 (el) |
| PT (1) | PT3068869T (el) |
| RS (1) | RS60929B1 (el) |
| SI (1) | SI3068869T1 (el) |
| WO (1) | WO2015073988A1 (el) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2881463A1 (en) * | 2013-12-09 | 2015-06-10 | DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH | Factor IX variants with clotting activity in absence of their cofactor and/or with increased F.IX clotting activity and their use for treating bleeding disorders |
| GB201420139D0 (en) | 2014-11-12 | 2014-12-24 | Ucl Business Plc | Factor IX gene therapy |
| GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
| CA3043995A1 (en) * | 2015-11-16 | 2017-05-26 | The Trustees Of The University Of Pennsylvania | Targeted delivery of therapeutic proteins bioencapsulated in plant cells to cell types of interest for the treatment of disease |
| JP7145083B2 (ja) * | 2016-03-20 | 2022-09-30 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 高等植物の葉緑体におけるトランス遺伝子発現を増加させるためのコドン最適化及びリボソームプロファイリング |
| US10842885B2 (en) | 2018-08-20 | 2020-11-24 | Ucl Business Ltd | Factor IX encoding nucleotides |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110179530A1 (en) | 2001-01-23 | 2011-07-21 | University Of Central Florida Research Foundation, Inc. | Pharmaceutical Proteins, Human Therapeutics, Human Serum Albumin Insulin, Native Cholera Toxin B Subunit on Transgenic Plastids |
| WO2004005467A2 (en) | 2002-07-03 | 2004-01-15 | University Of Central Florida | Expression of human interferon in transgenic chloroplasts |
| CA2402066C (en) | 2000-03-01 | 2015-09-29 | Auburn University | Plastid transformation vectors for expressing human proteins in plants |
| CA2401954A1 (en) | 2000-03-02 | 2001-09-07 | Auburn University | Marker free transgenic plants: engineering the chloroplast genome without the use of antibiotic selection |
| EP1456390B1 (en) | 2001-12-26 | 2011-03-02 | University Of Central Florida | Expression of protective antigens in transgenic chloroplasts and the production of improved vaccines |
| AU2005280659A1 (en) * | 2004-05-11 | 2006-03-09 | Wyeth | Novel polynucleotides related to oligonucleotide arrays to monitor gene expression |
| GB0709803D0 (en) | 2007-05-22 | 2007-07-04 | Ucl Business Plc | Predictive method |
| US9724400B2 (en) | 2009-11-09 | 2017-08-08 | The Trustees Of The University Of Pennsylvania | Administration of plant expressed oral tolerance agents |
| US8454957B2 (en) * | 2010-06-17 | 2013-06-04 | Stemnion, Inc. | Methods for treating coagulation disorders |
| US20130017997A1 (en) * | 2010-08-19 | 2013-01-17 | Amunix Operating Inc. | Factor VIII Compositions and Methods of Making and Using Same |
| US10865419B2 (en) | 2011-10-24 | 2020-12-15 | The Trustees Of The University Of Pennsylvania | Orally administered plastid expressed cholera toxin B subunit-exendin 4 as treatment for type 2 diabetes |
| LT2802668T (lt) * | 2012-01-12 | 2018-11-26 | Bioverativ Therapeutics Inc. | Imunogeninio atsako prieš faktorių viii individuose, kuriems skiriama faktoriaus viii terapija, sumažinimas |
-
2014
- 2014-11-17 LT LTEP14862042.0T patent/LT3068869T/lt unknown
- 2014-11-17 SI SI201431680T patent/SI3068869T1/sl unknown
- 2014-11-17 PL PL14862042T patent/PL3068869T3/pl unknown
- 2014-11-17 PT PT148620420T patent/PT3068869T/pt unknown
- 2014-11-17 EP EP14862042.0A patent/EP3068869B1/en active Active
- 2014-11-17 CA CA2967269A patent/CA2967269C/en active Active
- 2014-11-17 US US15/037,045 patent/US10233216B2/en active Active
- 2014-11-17 WO PCT/US2014/065994 patent/WO2015073988A1/en active Application Filing
- 2014-11-17 DK DK14862042.0T patent/DK3068869T3/da active
- 2014-11-17 AU AU2014348289A patent/AU2014348289B2/en active Active
- 2014-11-17 HU HUE14862042A patent/HUE050869T2/hu unknown
- 2014-11-17 EP EP20185791.9A patent/EP3763381A1/en not_active Withdrawn
- 2014-11-17 RS RS20201237A patent/RS60929B1/sr unknown
- 2014-11-17 ES ES14862042T patent/ES2821882T3/es active Active
-
2019
- 2019-03-12 US US16/299,928 patent/US10556932B2/en active Active
-
2020
- 2020-02-11 US US16/787,778 patent/US20200270313A1/en not_active Abandoned
- 2020-10-19 HR HRP20201680TT patent/HRP20201680T1/hr unknown
- 2020-10-22 CY CY20201101009T patent/CY1123792T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2821882T3 (es) | 2021-04-28 |
| HUE050869T2 (hu) | 2021-01-28 |
| EP3763381A1 (en) | 2021-01-13 |
| AU2014348289A1 (en) | 2016-06-16 |
| AU2014348289B2 (en) | 2020-11-26 |
| EP3068869A4 (en) | 2017-04-05 |
| EP3068869A1 (en) | 2016-09-21 |
| LT3068869T (lt) | 2020-10-26 |
| WO2015073988A1 (en) | 2015-05-21 |
| PL3068869T3 (pl) | 2021-03-08 |
| PT3068869T (pt) | 2020-10-08 |
| RS60929B1 (sr) | 2020-11-30 |
| US10233216B2 (en) | 2019-03-19 |
| SI3068869T1 (sl) | 2020-11-30 |
| HRP20201680T1 (hr) | 2021-03-19 |
| US20160289277A1 (en) | 2016-10-06 |
| US20190194265A1 (en) | 2019-06-27 |
| CA2967269C (en) | 2022-04-26 |
| US10556932B2 (en) | 2020-02-11 |
| US20200270313A1 (en) | 2020-08-27 |
| DK3068869T3 (da) | 2020-09-07 |
| EP3068869B1 (en) | 2020-07-22 |
| CA2967269A1 (en) | 2015-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123792T1 (el) | Συνθεσεις για καταστολη σχηματiσμου αναστολεων εναντι του παραγοντα viii σε ασθενεις με αιμορροφιλια α | |
| CY1124298T1 (el) | Φενφλουραμινη για χρηση στην θεραπευτικη αντιμετωπιση του συνδρομου dravet | |
| CY1124311T1 (el) | Παρεμποδιστες dna-pk | |
| CY1125613T1 (el) | 4-ιμιδαζοπυριδαζιν-1-υλ-βενζαμιδια και 4- ιμιδαζοτριαζιν-1-υλ-βενζαμιδια ως αναστολεις βτκ | |
| CY1121148T1 (el) | Παραγοντες συνδεσης vegf/dll4 και χρησεις αυτων | |
| CY1121538T1 (el) | Μονοκλωνικα αντισωματα εναντι του αναστολεα του μονοπατιου ιστικου παραγοντα (tfpi) | |
| CY1124000T1 (el) | Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες σε κρυσταλλικη μορφη | |
| CY1122349T1 (el) | Παραγωγα 1-benzyλ-3-υδροξυμεθυλινδαζολης και χρηση αυτων στη θεραπεια νοσων που βασιζονται στην εκφραση των mcp-1, cxcr1 και ρ40 | |
| CY1121360T1 (el) | Αναστολεις dna-pk | |
| CY1119454T1 (el) | Αντισωματα εναντι cd38 για τη θεραπεια του πολλαπλου μυελωματος | |
| CY1119410T1 (el) | Βελτιστοποιημενα μονοκλωνικα αντισωματα εναντι του αναστολεα της οδου του ιστικου παραγοντα (tfpi) | |
| CY1122456T1 (el) | Μονοκλωνικα αντισωματα εναντιον παραγοντα 15 αυξησης και διαφοροποιησης (gdf-15), και χρησεις αυτων για θεραπευτικη αγωγη καρκινικης καχεξιας και καρκινου | |
| CY1117372T1 (el) | Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες και η χρηση τους | |
| CY1119490T1 (el) | Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων | |
| CY1116315T1 (el) | Παραγωγα κιναζολιν-4(3η)-ονης που χρησιμοποιουνται ως αναστολεις κινασης ρι3 | |
| EA201592200A1 (ru) | Производные сульфамоилпирроламида и их применение в качестве медикаментов для лечения гепатита b | |
| CY1117584T1 (el) | Παραγωγα 1-βενζυλ-3-υδροξυμεθυλινδαζολης και η χρηση τους στη θεραπευτικη αντιμετωπιση νοσων που βασιζονται στην εκφραση των mcp-1, cx3cr1 | |
| EA201591890A1 (ru) | Производные n-фенилкарбоксамида и их применение в качестве лекарственных препаратов для лечения гепатита b | |
| EA201390772A1 (ru) | Новые соли и полиморфные формы афатиниба | |
| CY1126109T1 (el) | Αναστολεις toy trpc6 | |
| EA201490647A1 (ru) | Производные бензотиазол-6-илуксусной кислоты и их применение для лечения вич-инфекции | |
| EA201300558A1 (ru) | Соединения и способы для купирования боли | |
| CR20120490A (es) | Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf) | |
| CY1121628T1 (el) | 7-βενζυλ-4-(2-μεθυλοβενζυλ)-2,4,6,7,8,9-εξαϋδροϊμιδαζο[1,2-α]πυριδο[3,4-ε]πυριμιδιν-5(1η)-ονη, αλατα αυτης και μεθοδοι χρησης | |
| CY1116234T1 (el) | Υποκατεστημενα 2-οξυ-κινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3 |